LC-MS/MS studies for identification and characterization of new forced degradation products of dabrafenib and establishment of their degradation pathway

Development and validation of HPTLC method for simultaneous estimation of bioactive components in combined extracts of three hepatoprotective plants

(2021) Sharuti Mehta et al.   JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES

Simultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry

(2020) David Balakirouchenane et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

LC and LC–MS/MS studies for identification and characterization of new degradation products of ibrutinib and elucidation of their degradation pathway

(2020) Lovekesh Mehta et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC‐MS/MS

(2019) Stefanie Krens et al.   BIOMEDICAL CHROMATOGRAPHY

Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study

(2017) Yutaka Fujiwara et al.   INVESTIGATIONAL NEW DRUGS

Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography–tandem mass spectrometry

(2016) C.M. Nijenhuis et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas

(2014) Priscilla K Brastianos et al.   NATURE GENETICS

BRAFmutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis

(2013) C. Clancy et al.   Colorectal Disease

Liquid chromatography–tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma

(2013) Rolf W. Sparidans et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

The role of BRAF V600 mutation in melanoma

(2012) Paolo A Ascierto et al.   Journal of Translational Medicine

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

BRAFMutations in Hairy-Cell Leukemia

(2011) Enrico Tiacci et al.   NEW ENGLAND JOURNAL OF MEDICINE